{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056940","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.070060+00:00","generated_at":"2026-06-02T05:59:02.611559+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start","bullets":["Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.","R&D expenses rose to $44.3M from $39.5M, driven by azetukalner manufacturing and personnel costs.","Phase 3 MDD program to start H2 2024 after successful FDA interactions; X-TOLE2 enrollment completion expected late 2024 to early 2025.","WHO and USAN approved 'azetukalner' as generic name for XEN1101, a Kv7 potassium channel opener.","Other income increased to $11.5M from $7.6M on higher interest; cash expected to fund operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056940","json":"https://secwatch.observer/filing/0000950170-24-056940.json","markdown":"https://secwatch.observer/filing/0000950170-24-056940.md","text":"https://secwatch.observer/filing/0000950170-24-056940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/0000950170-24-056940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/xene-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:59:02.611559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97eb264eaf912218933eb03a229cd1694ebef09d","claim":"Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024056940/0000950170-24-056940-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}